WallStreetZenWallStreetZen

NASDAQ: ACIU
Ac Immune Sa Stock

$3.60-0.28 (-7.22%)
Updated Jul 17, 2024
ACIU Price
$3.60
Fair Value Price
$0.65
Market Cap
$357.11M
52 Week Low
$2.20
52 Week High
$5.14
P/E
-5.37x
P/B
2.25x
P/S
17.46x
PEG
N/A
Dividend Yield
N/A
Revenue
$16.26M
Earnings
-$62.03M
Gross Margin
100%
Operating Margin
-367.95%
Profit Margin
-368.8%
Debt to Equity
0.16
Operating Cash Flow
-$49M
Beta
0.98
Next Earnings
Aug 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ACIU Overview

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ACIU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ACIU ($3.60) is overvalued by 455.31% relative to our estimate of its Fair Value price of $0.65 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ACIU ($3.60) is not significantly undervalued (455.31%) relative to our estimate of its Fair Value price of $0.65 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ACIU is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACIU due diligence checks available for Premium users.

Be the first to know about important ACIU news, forecast changes, insider trades & much more!

ACIU News

Valuation

ACIU fair value

Fair Value of ACIU stock based on Discounted Cash Flow (DCF)
Price
$3.60
Fair Value
$0.65
Overvalued by
455.31%
ACIU ($3.60) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACIU ($3.60) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACIU is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ACIU price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-5.37x
Industry
-21.17x
Market
30.24x

ACIU price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.25x
Industry
6.35x
ACIU is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ACIU's financial health

Profit margin

Revenue
$0.0
Net Income
-$20.3M
Profit Margin
0%
ACIU's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ACIU's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$190.1M
Liabilities
$25.7M
Debt to equity
0.16
ACIU's short-term assets ($120.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACIU's short-term assets ($120.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACIU's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ACIU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$800.0k
Investing
-$26.8M
Financing
-$781.8k
ACIU's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ACIU vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ACIU$357.11M-7.22%-5.37x2.25x
INZY$355.05M-0.52%-4.19x2.99x
VNDA$361.99M-0.16%-69.11x0.67x
XERS$363.23M-4.67%-5.33x-39.58x
CABA$364.97M-3.82%-4.40x1.65x

Ac Immune Sa Stock FAQ

What is Ac Immune Sa's quote symbol?

(NASDAQ: ACIU) Ac Immune Sa trades on the NASDAQ under the ticker symbol ACIU. Ac Immune Sa stock quotes can also be displayed as NASDAQ: ACIU.

If you're new to stock investing, here's how to buy Ac Immune Sa stock.

What is the 52 week high and low for Ac Immune Sa (NASDAQ: ACIU)?

(NASDAQ: ACIU) Ac Immune Sa's 52-week high was $5.14, and its 52-week low was $2.20. It is currently -29.96% from its 52-week high and 63.64% from its 52-week low.

How much is Ac Immune Sa stock worth today?

(NASDAQ: ACIU) Ac Immune Sa currently has 99,197,829 outstanding shares. With Ac Immune Sa stock trading at $3.60 per share, the total value of Ac Immune Sa stock (market capitalization) is $357.11M.

Ac Immune Sa stock was originally listed at a price of $15.66 in Sep 23, 2016. If you had invested in Ac Immune Sa stock at $15.66, your return over the last 7 years would have been -77.01%, for an annualized return of -18.94% (not including any dividends or dividend reinvestments).

How much is Ac Immune Sa's stock price per share?

(NASDAQ: ACIU) Ac Immune Sa stock price per share is $3.60 today (as of Jul 17, 2024).

What is Ac Immune Sa's Market Cap?

(NASDAQ: ACIU) Ac Immune Sa's market cap is $357.11M, as of Jul 18, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Ac Immune Sa's market cap is calculated by multiplying ACIU's current stock price of $3.60 by ACIU's total outstanding shares of 99,197,829.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.